{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["64"],"submitter":["Bar J"],"pubmed_abstract":["<h4>Background and purpose</h4>c-Met (also known as MET) protein is encoded by the MET proto-oncogene. In non-small cell lung cancer (NSCLC), c-Met protein overexpression (OE) drives tumorigenesis and is a therapeutic target, given recent US Food and Drug Administration approval of telisotuzumab vedotin-tllv. This retrospective analysis of tumor samples and clinical data from real-world patients with non-squamous NSCLC characterized the prevalence of c-Met protein OE, its association with messenger ribonucleic acid (mRNA) expression, MET gene amplification, programmed-death ligand 1 (PD-L1) expression, and its impact on prognosis.<h4>Patients and methods</h4>A patient cohort was selected for manual abstraction of clinical data from electronic health records. Patients were selected based on"],"journal":["Acta oncologica (Stockholm, Sweden)"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12640106"],"repository":["biostudies-literature"],"pubmed_title":["Prevalence, molecular characterization, and prognosis of c-Met protein overexpression in a real-world cohort of patients with non-squamous non-small cell lung cancer."],"pmcid":["PMC12640106"],"pubmed_authors":["Ratajczak C","Baijal S","Jiang F","Zhao W","Cai MH","Choi YC","Liede A","Ansell PJ","Vasilopoulos A","Bar J","Roberts-Rapp L","Camidge DR","Lu S","Simmons A"],"additional_accession":[]},"is_claimable":false,"name":"Prevalence, molecular characterization, and prognosis of c-Met protein overexpression in a real-world cohort of patients with non-squamous non-small cell lung cancer.","description":"<h4>Background and purpose</h4>c-Met (also known as MET) protein is encoded by the MET proto-oncogene. In non-small cell lung cancer (NSCLC), c-Met protein overexpression (OE) drives tumorigenesis and is a therapeutic target, given recent US Food and Drug Administration approval of telisotuzumab vedotin-tllv. This retrospective analysis of tumor samples and clinical data from real-world patients with non-squamous NSCLC characterized the prevalence of c-Met protein OE, its association with messenger ribonucleic acid (mRNA) expression, MET gene amplification, programmed-death ligand 1 (PD-L1) expression, and its impact on prognosis.<h4>Patients and methods</h4>A patient cohort was selected for manual abstraction of clinical data from electronic health records. Patients were selected based on","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-06-05T17:31:58.102Z","creation":"2026-06-05T03:07:38.038Z"},"accession":"S-EPMC12640106","cross_references":{"pubmed":["41254996"],"doi":["10.2340/1651-226X.2025.44344"]}}